Fifth annual meeting of the Measles and Rubella Elimination Regional Monitoring and Re-Verification Commission. Mexico City, 4–7 November 2025

This report presents the deliberations and conclusions of the Fifth Annual Meeting of the Measles and Rubella Elimination Regional Monitoring and Re‑Verification Commission (RVC), convened in Mexico City from 4 to 7 November 2025. The meeting assessed the epidemiological situation of measles, rubella, and congenital rubella syndrome (CRS) in the Region of the Americas, reviewed progress on previous recommendations, and evaluated country performance against the Regional Framework for sustaining elimination. The Region faces a critical juncture. After years of low transmission, measles has resurged dramatically, with 12,466 confirmed cases reported in 2025 compared to 466 in 2024. Endemic transmission has been reestablished in Canada, resulting in the loss of the Region’s verification as measles-free—a historic setback for the Americas. Rubella and CRS elimination status remain intact across all countries. This publication provides detailed country classifications, surveillance indicators, and laboratory findings, including molecular epidemiology data that identified genotype D8 (DSID 9171) as the predominant lineage in 2025 outbreaks. It also documents persistent challenges: suboptimal vaccination coverage, immunity gaps, vaccine hesitancy, and inequities affecting Indigenous and vulnerable populations. Despite improvements in surveillance and laboratory capacity, delayed outbreak detection and uneven political commitment continue to threaten sustainability. The RVC issues clear recommendations for urgent action: strengthen immunization programs, enhance surveillance systems, ensure rapid outbreak response, and maintain robust laboratory capacity. The report underscores the need for coordinated regional strategies and sustained political and financial commitment to prevent further erosion of elimination gains.